Smith & Nephew (SNN)

Citi has reiterated its buy rating on Smith & Nephew PLC (LSE:SN) following recent meetings with the company's CEO and CFO. The bank highlights a constructive tone around the business despite the deci...

Smith & Nephew's interim results confirm solid progress, with revenue up 5% and strong cash flow growth, supporting my continued 'buy' rating. Dividend growth has resumed after years of stagnation, an...

Citi has stuck with its ‘buy' call on Smith & Nephew PLC (LSE:SN) after the company delivered quarterly results that were, in Citi's words, “meaningfully better than expected”, and announced a $500mn ...

Smith & Nephew plc (NYSE:SNN ) Q2 2025 Earnings Conference Call August 5, 2025 3:30 AM ET Company Participants Deepak S. Nath - CEO & Director John Terence Rogers - CFO & Executive Director Conference...

Smith & Nephew PLC (LSE:SN) shares surged 14% after the company reported robust revenue and profit growth, and announced a $500 million share buyback to be launched in the second half of the year. The...

As of Aug. 5, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Smith & Nephew PLC (LSE:SN) maintained full-year guidance after reporting robust revenue growth and rising profitability on Tuesday, as the medical technology company posted strong sets of results for...

Investors interested in Medical - Products stocks are likely familiar with Smith & Nephew (SNN) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity ri...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

It was a quiet start to the week for shares in Smith & Nephew PLC (LSE:SN). But perhaps it is the calm before the storm for the medical devices giant, which faces a shareholder revolt.